NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Synthace

Synthace

Private
London, EnglandEnterprise Softwarehttps://www.synthace.com

Last Round

Series C

Nov 16, 2021

Est. Valuation

$71.3M

Total Funding Raised

$76.37M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Synthace is a biotechnology company that offers a laboratory automation platform aimed at transforming biological experimentation by streamlining data management and facilitating the planning and execution of complex experiments.

Sector

Enterprise Software

Verticals

Drug Discovery, Biotechnology, Workflow Automation, Low-Code/No-Code, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

Life Sciences R&D Cloudlab automation softwareno-code lab automationDesign of ExperimentsDOEdrug discoveryscientific workflow automationanalysis-ready datalab orchestrationcloud labLab of the Futureexperiment simulationbioprocess developmentdigital biologyassay developmentCDMOAI scientist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synthace Comparables

Compare Synthace with similar companies based on industry and business-model similarity.

Synthace comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Labforward
82%
TetraScience
80%
Artificial, Inc.
80%

Synthace Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 16, 2021
Series BDec 12, 2018
Series ASep 19, 2017
SeedFeb 11, 2015
SeedSep 23, 2014
Grant
Mar 7, 2013

Key People

Founding team and executive leadership

Markus Gershater

Chief Scientific Officer And Cofounder

Founding Team

Synthace Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Added Charles River Laboratories International as a customer.

  • Apr 1, 2026

    Added GlaxoSmithKline, a pharmaceutical company, as a customer.

Synthace Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Synthace Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synthace's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon, England
Employee Range36
Year Founded2011
Last FundingNov 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.